The generic name for Ruxolitinib is ruxolitinib [1].
What is Ruxolitinib used for?
Ruxolitinib is a Janus kinase (JAK) inhibitor approved for the treatment of several conditions. It is used for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF [2]. It is also indicated for polycythemia vera (PV) in patients who have had an inadequate response to or are intolerant of hydroxyurea [2]. Additionally, ruxolitinib is approved for the treatment of acute graft-versus-host disease (GVHD) after failure of corticosteroids or another systemic therapy, and for chronic GVHD after failure of at least one prior systemic therapy [2].
How does Ruxolitinib work?
Ruxolitinib works by inhibiting Janus kinases (JAKs), specifically JAK1 and JAK2 [3]. These enzymes play a crucial role in signaling pathways that are involved in cell growth, differentiation, and immune function. In conditions like myelofibrosis and polycythemia vera, these pathways can be dysregulated, leading to excessive blood cell production and inflammation. By blocking JAK1 and JAK2, ruxolitinib helps to reduce these abnormal signaling processes, thereby alleviating symptoms and disease progression [3].
When does Ruxolitinib patent expire?
The patent expiry dates for ruxolitinib can vary depending on specific patents and regions. For instance, in the United States, a key patent for ruxolitinib was expected to expire around 2028 [4]. However, patent landscapes are complex and can involve multiple patents covering different aspects of the drug, such as composition of matter, formulation, and method of use. It is advisable to consult resources like DrugPatentWatch.com for the most up-to-date and detailed information on patent expiries and potential market entry for generic versions [4].
Who makes Ruxolitinib?
Ruxolitinib is manufactured by Incyte Corporation [5]. The brand name under which it is marketed is Jakafi in the United States and Canada, and Jakavi in Europe and other countries outside of the U.S. and Canada [2, 5].
Can generic versions of Ruxolitinib be available?
Generic versions of ruxolitinib may become available after the expiration of relevant patents and any associated market exclusivities. The availability of generics can depend on regulatory approvals and legal challenges to patents. As patent protections diminish, companies can seek approval to market generic alternatives, which typically leads to lower drug prices [4].
What are the side effects of Ruxolitinib?
Common side effects of ruxolitinib can include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, shortness of breath, fatigue, muscle spasms, headache, and weight gain [2]. More serious side effects can include infections, herpes zoster (shingles), and the development of certain types of cancers, such as non-melanoma skin cancer and lymphoid malignancies [2]. Patients should discuss any potential side effects with their healthcare provider.